Creative Medical Technology Holdings, Inc.
$2.10 +0.0300 -3.23% 6.7K
Company Overview
Creative Medical Technology Holdings is a pioneering commercial-stage biotechnology company specializing in innovative stem cell technologies across the fields of immunotherapy, urology, neurology, endocrinology, and orthopedics. The company's mission is to address significant unmet medical needs through the development and commercialization of regenerative medicine therapies.
Leveraging its proprietary cell-based platforms, Creative Medical has established a robust pipeline of FDA-cleared clinical programs, including breakthrough treatments for chronic lower back pain and Type 1 Diabetes (T1D). The company’s lead products, including ImmCelz™ and AlloStem™, utilize cutting-edge human xenofree cell technology, positioning Creative Medical as a leader in the regenerative medicine space.
With a strong financial position, an expanding intellectual property portfolio, and ongoing strategic collaborations, Creative Medical is poised to revolutionize the treatment landscape for a variety of chronic conditions, offering hope to millions of patients worldwide.
Value Proposition
Creative Medical Technology is pioneering the next generation of regenerative medicine through its innovative use of stem cell technology and artificial intelligence. The company is at the forefront of developing groundbreaking therapies that address critical unmet medical needs, particularly in the areas of immunotherapy, neurology, and orthopedics.
The company’s progress in its Type 1 Diabetes and chronic lower back pain programs underscores its potential to revolutionize how these conditions are treated. With FDA authorizations to proceed with Phase I/II clinical trials in both indications, Creative Medical is advancing therapies that could significantly alter the treatment landscape for these chronic conditions, each multi-billion-dollar market opportunities, offering patients new hope where few effective options exist today.
Creative Medical Technology is also combining the power of AI with human induced pluripotent stem cells (iPSCs) to create personalized, precision treatments. The recent initiation of an AI-driven diagnostic and treatment program for patients exposed to biological and chemical agents showcases the company’s ability to rapidly adapt and apply emerging technologies.
Financially, Creative Medical Technology is in a strong position, with sufficient capital to advance its key programs without the immediate need for additional funding. This strategic positioning, combined with a focus on cutting-edge innovation and fiscal responsibility, makes Creative Medical Technology a compelling investment opportunity poised for transformative impact.
Programs
Investor Presentation
Investment Highlights
Innovative regenerative medicine pipeline with breakthrough technologies addressing unmet needs
- Broad portfolio targeting unmet needs in immunotherapy, urology, neurology, endocrinology, and orthopedics
- Lead programs, ImmCelz™ and AlloStem™, leverage xenofree cell technology for personalized treatments addressing Type 1 Diabetes and chronic lower back pain
- Type 1 Diabetes and chronic lower back pain each represent multi-billion-dollar market opportunities
- CELZ-101 received FDA Orphan Drug Designation for brittle Type 1 Diabetes, offering potential market exclusivity
Robust intellectual property portfolio
- Comprehensive patent protections strengthen long-term competitive position
Strategically leveraging artificial intelligence
- AI integration accelerates drug development and enhances personalized treatment plans
Strong financial position
- No long-term debt with cash reserves to support ongoing operations and clinical milestones
Experienced leadership
- Proven management team with a strong track record in advancing biotech innovations
Sign Up For CELZ Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Creative Medical Technology (CELZ) is a client of RedChip Companies. CELZ agreed to pay RedChip a one-time $45,000 fee for a national TV ad campaign aired weekdays from October 8 to October 18, 2024.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.